Fate Therapeutics (FATE) Return on Capital Employed (2013 - 2026)

Fate Therapeutics has reported Return on Capital Employed for 14 years, with the latest figure at 51.4% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 20.0% year-over-year to 51.4%; the trailing twelve-month figure through Mar 2026 stood at 51.4% (down 20.0% YoY), and the FY2025 full-year result was 42.97%, up 538.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 51.4%, down from 50.03% in the prior quarter.
• The five-year high for Return on Capital Employed was 30.2% in Q1 2022, with the low at 53.96% in Q2 2025.
• Historically, Return on Capital Employed has averaged 44.73% across 5 years, with a median of 43.23% in 2024.
• Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 2654 bps — and 2023, when it soared 1107 bps.
• Fate Therapeutics' Return on Capital Employed stood at 50.27% in 2022, then advanced by 22 bps to 39.21% in 2023, then dropped by 25 bps to 48.98% in 2024, then slipped by 2 bps to 50.03% in 2025, then dropped by 3 bps to 51.4% in 2026.
• The last three Return on Capital Employed figures came in at 51.4% (Q1 2026), 50.03% (Q4 2025), and 53.02% (Q3 2025), per Business Quant data.